Related Experiment Video
Updated: Jul 26, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in
1Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. srokudai@gunma-u.ac.jp.
Abstract:
TNBC is an aggressive and metastatic subtype of breast cancer in which TP53 mutation occurs frequently and is associated with particularly poor outcome. Mutations in TP53 can disrupt the intrinsic function of the tumor suppressor as well as acquire oncogenic gain-of-function (GOF) activities. However, little is known about its oncogenic GOF mediators and functions. Targeted therapy for TNBC patients is thus one of the most urgent needs in breast cancer therapeutics, and identifying genes that have synthetic lethal interactions with mutant TP53 may be a promising approach. In this chapter, we present procedures on sequential analysis of RNA-seq followed by high-throughput RNA interference screening (HTS-RNAi screening). This approach has been utilized to identify genes with synthetic lethality of mutant TP53, providing a promising strategy for the treatment of mutant TP53 in TNBC and determining its impact on tumorigenesis.
Insights
This study identifies genes with synthetic lethality in triple-negative breast cancer (TNBC) with TP53 mutations. This approach offers a promising strategy for developing targeted therapies for TNBC patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with frequent TP53 mutations, leading to poor patient outcomes.
- TP53 mutations can impair tumor suppressor functions and gain oncogenic gain-of-function (GOF) activities, but mediators are poorly understood.
Purpose of the Study:
- To identify genes interacting with mutant TP53 through synthetic lethality.
- To explore novel therapeutic strategies for TNBC targeting mutant TP53.
Main Methods:
- Sequential analysis of RNA-sequencing (RNA-seq) data.
- High-throughput RNA interference screening (HTS-RNAi) to identify synthetic lethal interactions.
Main Results:
- Identification of specific genes exhibiting synthetic lethality with mutant TP53.
- This screening approach successfully pinpointed potential therapeutic targets.
Conclusions:
- The developed methodology provides a robust strategy for discovering synthetic lethal interactions with mutant TP53 in TNBC.
- This research paves the way for targeted therapies aimed at treating TNBC with TP53 mutations and understanding their role in tumorigenesis.
